论文部分内容阅读
目的探讨胃癌患者术前胃蛋白酶原水平与临床病理指标的关系以及对术后生存预后的预测价值。方法入组的151例胃癌患者在手术前1周做胃蛋白酶原水平的检测,随后随访,收集患者的临床病理指标以及生存时间等。结果血清胃蛋白酶原检测结果显示,151例患者中,90例(59.6%)患者胃蛋白酶原阳性,61例(40.4%)患者胃蛋白酶原阴性。胃蛋白酶原阴性和胃癌患者的淋巴结转移、远处转移以及高临床分期具有显著的相关性,差异均有统计学意义(P<0.01)。生存分析结果表明,胃蛋白酶原检测阴性的患者5年总生存率(60.7%)及5年无复发生存率(56.7%)均明显低于阳性者(分别为80.5%、77.8%),差异均有统计学意义(P<0.01)。胃蛋白酶原阴性是胃癌不良预后的独立预测因素。结论血清胃蛋白酶原检测有可能做为预测胃癌预后的指标。
Objective To investigate the relationship between preoperative serum levels of pepsin and clinical and pathological parameters in patients with gastric cancer and their prognostic value. Methods One hundred and fifteen patients with gastric cancer who underwent gastric precocious puberty were tested for pepsin level one week before surgery. The patients were followed up and the clinical and pathological parameters and survival time were collected. Results Serum pepsinogen test results showed that of the 151 patients, 90 (59.6%) were positive for pepsinogen and 61 (40.4%) were negative for pepsinogen. Pepsinogen negative and gastric cancer patients with lymph node metastasis, distant metastasis and high clinical stage has a significant correlation, the differences were statistically significant (P <0.01). Survival analysis showed that the 5-year overall survival rate (60.7%) and 5-year recurrence-free survival rate (56.7%) were significantly lower in patients with negative gastric pepsin test (80.5%, 77.8%, respectively) There was statistical significance (P <0.01). Pepsinogen negative is an independent predictor of poor prognosis of gastric cancer. Conclusion Serum pepsinogen test may be used as a predictor of gastric cancer prognosis.